Written question asked by Joshua Reynolds (Liberal Democrat) on Thursday, 16 April 2026, in the House of Commons. It was due for an answer on Tuesday, 21 April 2026 (named day). A holding answer was provided on Wednesday, 22 April 2026. A substantive answer was provided by Zubir Ahmed (Labour) on Wednesday, 22 April 2026 on behalf of the Department of Health and Social Care.
Skin Diseases: Steroid Drugs
- Question
-
To ask the Secretary of State for Health and Social Care, what steps are being taken to ensure patients prescribed topical corticosteroids are informed of potential risks, including withdrawal reactions.
- Answer
-
Clinicians are expected to work with patients to make decisions about their care and treatment as part of shared decision-making, including discussing risks, benefits, and possible consequences of different options through information-sharing. Further information on shared decision-making can be found on the National Institute for Health and Care Excellence’s website:
Secondary information
- Type
- Written question
- Reference
- 128007
- Session
- 2024-26
- Subjects
- Labelling Steroid drugs Warnings Skin diseases
- Link
- View this Written question on www.parliament.uk
Librarians' tools
- Timestamp
- 2026-04-22 11:05:04 +0100
- URI
- http://data.parliament.uk/writtenparliamentaryquestion/commons/2024-26/128007
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/writtenparliamentaryquestion/commons/2024-26/128007
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/writtenparliamentaryquestion/commons/2024-26/128007